BTIG Analyst Sees AbbVie Acquiring Apogee as Positive
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 22 2026
0mins
BTIG analyst Julian Harrison says AbbVie (ABBV) can leverage its existing dermatology channels and compete in atopic dermatitis beyond JAK inhibitors with an acquisition of Apogee Therapeutics (APGE). Johnson & Johnson (JNJ), Pfizer (PFE), and Novartis (NVS) have strong dermatology channels but no prominent commercial presence in atopic dermatitis yet, and therefore could also be interested in acquiring Apogee, the analyst tells investors in a research note. BTIG views the Financial Times' report of AbbVie's potential buyout of Apogee as positive for other spinouts from Paragon Therapeutics, including Jade Biosciences (JBIO), Oruka Therapeutics (ORKA), Spyre Therapeutics (SYRE), and Crescent Biopharma (CBIO). The firm has a Buy rating on Apogee Therapeutics with a $137 price target. The stock in premarket trading is up 54%, or $49.10, to $139.48.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy APGE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on APGE
Wall Street analysts forecast APGE stock price to fall
15 Analyst Rating
13 Buy
2 Hold
0 Sell
Strong Buy
Current: 132.730
Low
83.00
Averages
105.67
High
137.00
Current: 132.730
Low
83.00
Averages
105.67
High
137.00
About APGE
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie Acquires Apogee to Strengthen Immunology Portfolio
- Acquisition Strategy: AbbVie announced its acquisition of Apogee Therapeutics for approximately $10.9 billion in cash, aimed at bolstering its immunology portfolio, particularly in light of the impending patent expirations of Skyrizi and Rinvoq, ensuring future growth drivers.
- Therapeutic Potential: The acquisition will provide AbbVie with several candidates, notably zumilokibart, an investigational therapy for eczema that has shown promise in mid-stage studies, potentially addressing unmet needs in the market and expected to enter phase 3 studies later this year.
- Market Opportunity: The eczema market was estimated at $19.4 billion last year, and if zumilokibart successfully passes phase 3 trials and gains approval, it could become a significant growth driver for AbbVie, further solidifying its leadership in the immunology space.
- Financial Robustness: AbbVie's Skyrizi and Rinvoq are projected to generate over $31 billion in combined revenue this year, and with a history of over 50 consecutive years of dividend increases, the company demonstrates strong financial health, making its stock attractive for income seekers.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies like Bio-Techne Corporation and Apogee Therapeutics for potential violations of federal securities laws and fiduciary duties, with Bio-Techne's sale to Merck KGaA at $73.00 per share in cash being a focal point.
- Shareholder Rights: Shareholders of Bio-Techne and Apogee Therapeutics are encouraged to contact the firm to learn about their rights and options, with Apogee's sale price set at $135.11 per share in cash, highlighting the firm's commitment to shareholder interests.
- Merger Transaction Impact: The merger between Boundless Bio and Serapha Bio is expected to result in Boundless Bio shareholders owning approximately 3.7% of the combined entity, while Chicago Atlantic Real Estate Finance's merger with Chicago Atlantic BDC will allow REFI shareholders to hold about 50.5% of the merged company, indicating significant changes in shareholder structure.
- Legal Service Commitment: Halper Sadeh LLC offers legal services on a contingency fee basis, ensuring no upfront costs for clients, aiming to support investors affected by securities fraud and corporate misconduct, thereby emphasizing its role in protecting investor rights.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Apogee Therapeutics, Inc. (NASDAQ: APGE) for its sale to AbbVie at $135.11 per share, potentially infringing on shareholder rights.
- Shareholder Rights: Open Lending Corporation (NASDAQ: LPRO) is being sold to ANV Group Holdings Ltd. for $3.15 per share, with Halper Sadeh LLC urging shareholders to be aware of their rights and options.
- Legal Consultation: Huntsman Corporation (NYSE: HUN) is selling to Olin Corporation for 0.5476 shares of Olin per Huntsman share, and Halper Sadeh LLC offers no-cost legal consultations to help shareholders understand their legal rights.
- Compensation Requests: Avanos Medical, Inc. (NYSE: AVNS) is being sold to American Industrial Partners for $25.00 per share, and Halper Sadeh LLC may seek increased compensation and other relief measures to protect shareholder interests.
See More
AbbVie Acquires Apogee Therapeutics for $10.9 Billion
- Acquisition Overview: AbbVie is acquiring Apogee Therapeutics for $10.9 billion at $135.11 per share in cash, representing a 49% premium, aimed at enhancing its drug portfolio and expanding its market share in immunology.
- Pipeline Advantages: Apogee brings a promising pipeline of experimental drugs targeting dermatologic, respiratory, and other immunological diseases, particularly its lead candidate, zumilokibart, which could become a best-in-class treatment for atopic dermatitis with a more convenient dosing schedule.
- Strategic Significance: AbbVie's CEO highlighted that this acquisition will further enrich its immunology portfolio, addressing significant patient needs in areas like atopic dermatitis and asthma, thereby reinforcing the company's leadership in inflammatory disease treatment.
- Financial Outlook: Although the deal is expected to close in the third quarter, AbbVie does not anticipate any impact on adjusted earnings per share until 2032, indicating a long-term strategic approach to diversifying its revenue base.
See More
AbbVie Acquires Apogee for $10.9 Billion to Strengthen Immunology Business
- Acquisition Overview: AbbVie is acquiring Apogee Therapeutics for $10.9 billion, paying $135.11 per share in cash, which represents a 49% premium over the stock's closing price prior to the announcement, aimed at diversifying its immunology business and enhancing profitability.
- Pipeline Potential: Apogee brings a promising pipeline of experimental drugs targeting dermatologic and respiratory diseases, with its lead candidate, zumilokibart, potentially being a best-in-class treatment for atopic dermatitis that offers a more convenient dosing schedule, addressing significant patient needs.
- Strategic Importance: AbbVie's CEO highlighted that this acquisition will expand its immunology portfolio in critical areas of patient need, helping to reduce reliance on blockbuster drugs Skyrizi and Rinvoq, which generated $6.6 billion in net revenue in the first quarter alone.
- Financial Outlook: While the acquisition is expected to close in the third quarter, AbbVie does not anticipate any contribution to its adjusted earnings per share until 2032, indicating a long-term strategic approach to enhancing its market position.
See More
Intel Shares Hit All-Time High as Market Confidence Grows
- Intel Stock Surge: Intel shares climbed to an all-time high of $141.45, driven by growing confidence in its chip manufacturing business and positive outlook on partnerships with major tech firms like Apple, which is expected to enhance future earnings.
- Keel Infrastructure Transformation: Keel Infrastructure reached a four-year high of $7.37 as investors welcomed its strategic shift from cryptocurrency mining to AI infrastructure, with the company raising $458 million to support its data center projects.
- Apogee Therapeutics Acquisition Boost: Apogee Therapeutics stock surged to $133 after AbbVie agreed to acquire the company for $135.11 per share in a $10.9 billion all-cash deal, indicating large pharmaceutical firms' ongoing interest in promising drug development.
- Strong Market Performance: Intel, Keel Infrastructure, and Apogee Therapeutics all achieved new 52-week highs, reflecting investor confidence in long-term growth in infrastructure, advanced computing, and healthcare sectors, with Intel and Keel both gaining over 5% and Apogee soaring 46%.
See More
AbbVie Acquires Apogee to Strengthen Immunology Portfolio
- Acquisition Strategy: AbbVie announced its acquisition of Apogee Therapeutics for approximately $10.9 billion in cash, aimed at bolstering its immunology portfolio, particularly in light of the impending patent expirations of Skyrizi and Rinvoq, ensuring future growth drivers.
- Therapeutic Potential: The acquisition will provide AbbVie with several candidates, notably zumilokibart, an investigational therapy for eczema that has shown promise in mid-stage studies, potentially addressing unmet needs in the market and expected to enter phase 3 studies later this year.
- Market Opportunity: The eczema market was estimated at $19.4 billion last year, and if zumilokibart successfully passes phase 3 trials and gains approval, it could become a significant growth driver for AbbVie, further solidifying its leadership in the immunology space.
- Financial Robustness: AbbVie's Skyrizi and Rinvoq are projected to generate over $31 billion in combined revenue this year, and with a history of over 50 consecutive years of dividend increases, the company demonstrates strong financial health, making its stock attractive for income seekers.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies like Bio-Techne Corporation and Apogee Therapeutics for potential violations of federal securities laws and fiduciary duties, with Bio-Techne's sale to Merck KGaA at $73.00 per share in cash being a focal point.
- Shareholder Rights: Shareholders of Bio-Techne and Apogee Therapeutics are encouraged to contact the firm to learn about their rights and options, with Apogee's sale price set at $135.11 per share in cash, highlighting the firm's commitment to shareholder interests.
- Merger Transaction Impact: The merger between Boundless Bio and Serapha Bio is expected to result in Boundless Bio shareholders owning approximately 3.7% of the combined entity, while Chicago Atlantic Real Estate Finance's merger with Chicago Atlantic BDC will allow REFI shareholders to hold about 50.5% of the merged company, indicating significant changes in shareholder structure.
- Legal Service Commitment: Halper Sadeh LLC offers legal services on a contingency fee basis, ensuring no upfront costs for clients, aiming to support investors affected by securities fraud and corporate misconduct, thereby emphasizing its role in protecting investor rights.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Apogee Therapeutics, Inc. (NASDAQ: APGE) for its sale to AbbVie at $135.11 per share, potentially infringing on shareholder rights.
- Shareholder Rights: Open Lending Corporation (NASDAQ: LPRO) is being sold to ANV Group Holdings Ltd. for $3.15 per share, with Halper Sadeh LLC urging shareholders to be aware of their rights and options.
- Legal Consultation: Huntsman Corporation (NYSE: HUN) is selling to Olin Corporation for 0.5476 shares of Olin per Huntsman share, and Halper Sadeh LLC offers no-cost legal consultations to help shareholders understand their legal rights.
- Compensation Requests: Avanos Medical, Inc. (NYSE: AVNS) is being sold to American Industrial Partners for $25.00 per share, and Halper Sadeh LLC may seek increased compensation and other relief measures to protect shareholder interests.
See More
AbbVie Acquires Apogee Therapeutics for $10.9 Billion
- Acquisition Overview: AbbVie is acquiring Apogee Therapeutics for $10.9 billion at $135.11 per share in cash, representing a 49% premium, aimed at enhancing its drug portfolio and expanding its market share in immunology.
- Pipeline Advantages: Apogee brings a promising pipeline of experimental drugs targeting dermatologic, respiratory, and other immunological diseases, particularly its lead candidate, zumilokibart, which could become a best-in-class treatment for atopic dermatitis with a more convenient dosing schedule.
- Strategic Significance: AbbVie's CEO highlighted that this acquisition will further enrich its immunology portfolio, addressing significant patient needs in areas like atopic dermatitis and asthma, thereby reinforcing the company's leadership in inflammatory disease treatment.
- Financial Outlook: Although the deal is expected to close in the third quarter, AbbVie does not anticipate any impact on adjusted earnings per share until 2032, indicating a long-term strategic approach to diversifying its revenue base.
See More
AbbVie Acquires Apogee for $10.9 Billion to Strengthen Immunology Business
- Acquisition Overview: AbbVie is acquiring Apogee Therapeutics for $10.9 billion, paying $135.11 per share in cash, which represents a 49% premium over the stock's closing price prior to the announcement, aimed at diversifying its immunology business and enhancing profitability.
- Pipeline Potential: Apogee brings a promising pipeline of experimental drugs targeting dermatologic and respiratory diseases, with its lead candidate, zumilokibart, potentially being a best-in-class treatment for atopic dermatitis that offers a more convenient dosing schedule, addressing significant patient needs.
- Strategic Importance: AbbVie's CEO highlighted that this acquisition will expand its immunology portfolio in critical areas of patient need, helping to reduce reliance on blockbuster drugs Skyrizi and Rinvoq, which generated $6.6 billion in net revenue in the first quarter alone.
- Financial Outlook: While the acquisition is expected to close in the third quarter, AbbVie does not anticipate any contribution to its adjusted earnings per share until 2032, indicating a long-term strategic approach to enhancing its market position.
See More
Intel Shares Hit All-Time High as Market Confidence Grows
- Intel Stock Surge: Intel shares climbed to an all-time high of $141.45, driven by growing confidence in its chip manufacturing business and positive outlook on partnerships with major tech firms like Apple, which is expected to enhance future earnings.
- Keel Infrastructure Transformation: Keel Infrastructure reached a four-year high of $7.37 as investors welcomed its strategic shift from cryptocurrency mining to AI infrastructure, with the company raising $458 million to support its data center projects.
- Apogee Therapeutics Acquisition Boost: Apogee Therapeutics stock surged to $133 after AbbVie agreed to acquire the company for $135.11 per share in a $10.9 billion all-cash deal, indicating large pharmaceutical firms' ongoing interest in promising drug development.
- Strong Market Performance: Intel, Keel Infrastructure, and Apogee Therapeutics all achieved new 52-week highs, reflecting investor confidence in long-term growth in infrastructure, advanced computing, and healthcare sectors, with Intel and Keel both gaining over 5% and Apogee soaring 46%.
See More
